US2008070259A1PendingUtilityA1
Novel Human Enzymes of the Metalloprotease Family
Est. expiryNov 19, 2019(expired)· nominal 20-yr term from priority
A61P 7/02A61P 9/00A61P 37/00A61P 37/08A61P 7/10A61P 9/10A61P 9/12A61P 3/04A61P 9/06A61P 9/04A61P 31/04A61P 25/00A61P 35/00A61P 31/12A61P 25/04A61P 25/36A61P 31/18A61P 25/22A61P 25/28A61P 25/16A61P 25/30A61P 25/20A61P 3/10A61P 25/06A61P 25/08A61P 25/18A61P 31/10A61P 25/14A61P 25/24A61P 29/00A61P 33/02A61P 19/02C12Q 2600/158G01N 2500/00C12N 9/6497G01N 33/573A61P 1/12C12N 9/6489A61P 13/12A61P 1/08G01N 2333/96486C12Q 2600/156A61P 19/10C12Q 1/6883G01N 2500/04C12Y 304/24071A61P 13/08A61P 11/06A61P 1/04
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates to newly identified polypeptides which have zinc metalloprotease activities and are referred to as IGS5, and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be stimulators and/or inhibitors which are useful in therapy, to antibodies specific to such peptides, and to production of such polypeptides and polynucleotides.
Claims
exact text as granted — not AI-modified1 . A method of diagnosing a disease or susceptibility to a disease in a subject related to expression or activity of a polypeptide having a zinc metalloprotease activity and consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6 in a subject comprising one or more steps of: (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and (b) comparing a level of expression of the polypeptide a sample derived from said subject with a standard base level.
Join the waitlist — get patent alerts
Track US2008070259A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.